The joint venture — the first in the field of biotechnology — would produce vaccines to fight cancer developed with Cuban technology. U.S. clinical trials of the CIMAvax vaccine against lung cancer began in January, under an authorization from the Food and Drug Administration.
The joint venture — the first in the field of biotechnology — would produce vaccines to fight cancer developed with Cuban technology. U.S. clinical trials of the CIMAvax vaccine against lung cancer began in January, under an authorization from the Food and Drug Administration. Courtesy
The joint venture — the first in the field of biotechnology — would produce vaccines to fight cancer developed with Cuban technology. U.S. clinical trials of the CIMAvax vaccine against lung cancer began in January, under an authorization from the Food and Drug Administration. Courtesy